Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
Public ClinicalTrials.gov record NCT02696031. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week 104 (core phase) followed by an optional extension phase consisting of a 16-week randomized dose escalation treatment period and a continuous treatment period for up to Week 208
Study identification
- NCT ID
- NCT02696031
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 555 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2016 (Actual)
- Primary completion
- Jul 1, 2019 (Actual)
- Completion
- Mar 11, 2021 (Actual)
- Last update posted
- Apr 29, 2022
2016 – 2021
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35205 | — |
| Novartis Investigative Site | Beverly Hills | California | 90211 | — |
| Novartis Investigative Site | Fullerton | California | 92835 | — |
| Novartis Investigative Site | Denver | Colorado | 80230 | — |
| Novartis Investigative Site | Gainesville | Florida | 32608 | — |
| Novartis Investigative Site | Idaho Falls | Idaho | 83404 | — |
| Novartis Investigative Site | Bowling Green | Kentucky | 42101 | — |
| Novartis Investigative Site | Lansing | Michigan | 48910 | — |
| Novartis Investigative Site | Great Falls | Montana | 59405 | — |
| Novartis Investigative Site | Albany | New York | 12206 | — |
| Novartis Investigative Site | Potsdam | New York | 13676 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28204 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73102 | — |
| Novartis Investigative Site | Portland | Oregon | 97239 | — |
| Novartis Investigative Site | Duncansville | Pennsylvania | 16635 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29460 | — |
| Novartis Investigative Site | Leander | Texas | 78641 | — |
| Novartis Investigative Site | Mesquite | Texas | 75150 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 121 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02696031, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2022 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02696031 live on ClinicalTrials.gov.